Latest Period
Q2 2026
Security Snapshot
AN2 Therapeutics, Inc. - Common Stock (ANTX) Institutional Ownership
CUSIP: 037326105
13F Institutional Holders and Ownership History from Q1 2022 to Q2 2026
Institutions Reporting
66
Shares (Excl. Options)
24,584,035
Price
$4.84
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ANTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 24,584,035
- Total 13F value
- $118,990,931
- Portfolio coverage rank
- 0%
- Share change
- +2,709,448
- Value change
- +$15,325,436
- Number of holders
- 66
- Shares outstanding
- 36,076,317
- SEC-reported price per share
- $5.00
- Insider filing price
- $5.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ANTX - AN2 Therapeutics, Inc. - Common Stock is tracked under CUSIP 037326105.
- 66 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 52 to 66 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $74,776,572 to $118,990,931.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 66 institutions filings for Q2 2026.
Security key
037326105
Latest holder period
Q2 2026
13F holders
66
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
ANTX full holder history
AN2 Therapeutics, Inc. SEC filings
AN2 Therapeutics, Inc. company facts
AN2 Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 037326105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ANTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $4,880,614 | 3,697,435 | Commodore Capital LP | 09 Mar 2026 | |||
| Vivo Opportunity Fund Holdings, L.P. | 8% | $3,780,937 | 2,864,346 | Vivo Opportunity Fund Holdings, L.P. | 10 Mar 2026 | |||
| Coastlands Capital Partners LP | 9.3% | $3,632,511 | 2,815,900 | Coastlands Capital LP | 28 May 2025 | |||
| Adjuvant Global Health Technology Fund, L.P. | 7.9% | $3,061,815 | 2,373,500 | Adjuvant Capital GP, L.P. | 31 Dec 2024 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 6.3% | $2,952,975 | 2,237,102 | Millennium Management LLC | 06 Mar 2026 | |||
| Easom Eric | 7.9% | +28% | $2,946,245 | +$447,311 | 2,232,004 | +18% | Eric Easom | 31 Dec 2025 |
| Almitas Capital LLC | 4.1% | -26% | $7,011,071 | -$7,091,206 | 1,479,129 | -50% | Almitas Capital LLC | 31 Mar 2026 |
| Brii Biosciences Ltd | 3.1% | $1,196,089 | 927,201 | Brii Biosciences Limited | 31 Dec 2024 | |||
| BML Investment Partners, L.P. | 1.4% | -85% | $551,387 | -$3,599,088 | 427,432 | -87% | BML Investment Partners, L.P. | 17 Jun 2025 |
As of 30 Jun 2026, 66 institutional investors reported holding 24,584,035 shares of AN2 Therapeutics, Inc. - Common Stock (ANTX). This represents 68% of the company’s total 36,076,317 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
65%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 8.7% | 3,153,640 | 0% | 1.4% | $15,263,618 |
| Commodore Capital LP | 8.1% | 2,933,680 | +26% | 0.85% | $14,199,011 |
| MILLENNIUM MANAGEMENT LLC | 6.4% | 2,318,692 | +4.3% | 0.01% | $11,222,469 |
| BlackRock, Inc. | 4.6% | 1,665,494 | +422% | 0% | $8,060,991 |
| Spruce Street Capital LP | 4.6% | 1,661,073 | 0% | 1.6% | $8,039,593 |
| Almitas Capital LLC | 4.1% | 1,469,129 | -0.68% | 1.7% | $7,110,584 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,238,705 | +23% | 0% | $5,995,332 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.8% | 1,000,000 | 0% | 0.01% | $4,840,000 |
| CITADEL ADVISORS LLC | 2.6% | 951,997 | +513% | 0% | $4,607,665 |
| Boxer Capital Management, LLC | 2.1% | 749,035 | 0% | 0.27% | $3,625,329 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 697,806 | +144% | 0% | $3,378,664 |
| SummitTX Capital, L.P. | 1.7% | 597,453 | 0.08% | $2,891,673 | |
| Balyasny Asset Management L.P. | 1.5% | 556,027 | 0% | $2,691,171 | |
| Stonepine Capital Management, LLC | 1.5% | 551,692 | -23% | 2% | $2,670,190 |
| AMERIPRISE FINANCIAL INC | 1.5% | 537,064 | -23% | 0% | $2,599,390 |
| Sio Capital Management, LLC | 1.5% | 529,933 | -19% | 0.44% | $2,564,876 |
| Ally Bridge Group (NY) LLC | 1.5% | 526,315 | 0% | 3.3% | $2,547,365 |
| Prosight Management, LP | 1.3% | 474,638 | -8% | 0.4% | $2,297,248 |
| Woodline Partners LP | 1.3% | 459,805 | -54% | 0.01% | $2,225,456 |
| STATE STREET CORP | 0.86% | 311,602 | +170% | 0% | $1,508,154 |
| NORTHERN TRUST CORP | 0.6% | 214,921 | +398% | 0% | $1,040,217 |
| Seven Fleet Capital Management LP | 0.58% | 208,946 | +4.6% | 0.17% | $1,011,299 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 196,920 | +43% | 0% | $953,093 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.5% | 179,594 | 0% | $869,235 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 0.46% | 167,446 | -44% | 0.05% | $810,438 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q2 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 24,584,035 | $118,990,931 | +$15,325,436 | $4.84 | 66 |
| 2026 Q1 | 21,894,480 | $74,776,572 | +$47,799,586 | $3.42 | 52 |
| 2025 Q4 | 8,664,575 | $9,877,677 | +$437,838 | $1.14 | 37 |
| 2025 Q3 | 8,276,317 | $10,511,010 | +$7,414 | $1.27 | 35 |
| 2025 Q2 | 8,284,557 | $8,781,263 | -$8,600,258 | $1.06 | 36 |
| 2025 Q1 | 14,340,830 | $19,503,615 | -$264,699 | $1.36 | 37 |
| 2024 Q4 | 14,528,930 | $20,050,012 | +$893,482 | $1.38 | 37 |
| 2024 Q3 | 13,513,224 | $14,458,906 | -$16,315,888 | $1.07 | 31 |
| 2024 Q2 | 19,415,909 | $41,730,123 | -$1,462,207 | $2.15 | 45 |
| 2024 Q1 | 18,733,564 | $60,875,021 | -$18,042,573 | $3.25 | 54 |
| 2023 Q4 | 20,391,503 | $417,920,110 | +$9,592,150 | $20.49 | 51 |
| 2023 Q3 | 19,931,490 | $320,311,244 | +$132,978,201 | $16.08 | 37 |
| 2023 Q2 | 11,741,328 | $99,891,167 | +$18,097,549 | $8.50 | 30 |
| 2023 Q1 | 9,600,229 | $94,752,948 | -$1,565,644 | $9.87 | 37 |
| 2022 Q4 | 9,762,608 | $93,037,767 | -$3,679,262 | $9.53 | 35 |
| 2022 Q3 | 9,496,676 | $165,051,000 | +$1,938,968 | $17.38 | 35 |
| 2022 Q2 | 9,386,370 | $72,410,000 | +$2,199,519 | $7.75 | 32 |
| 2022 Q1 | 8,952,537 | $134,111,000 | +$134,111,000 | $15.07 | 18 |